Blend uniformity is an important factor in pharmaceutical manufacturing. A poor uniformity of the blend can cause the rejection of the product that can lead to the loss of revenue.
The particle size of the formulation ingredients can affect the physical properties of the product. Dissolution of the tablets is affected by the particle size of active ingredients.
De-mixing of the blend ingredients may occur due to the over blending of the bland. It can cause the segregation of the active material in the bland and finally can show the results out of blend uniformity limits. Therefore, it is important to validate the mixing time in the manufacturing process of tablet dosage forms.
Related: Sampling Procedure for Blander
The particle size of the ingredients plays a great role in the de-mixing process. A big difference in the particle size of the active ingredients and the excipients may cause the de-mixing. A fine powder form of the ingredients should be avoided. Unloading of the blend should be done carefully to avoid the de-mixing.
According to the FDA’s Blend Uniformity Analysis, a sample taken for the bland uniformity analysis should be equivalent to the weight of the dosage form and the whole sample should be taken for analysis. Blend uniformity analysis is not necessary to do when active ingredient in each dosage form is 50 mg or greater and when dosage unit contains more than 50 % of active ingredient. Blend is analyzed for uniformity of active contents to comply the limit (85-115%)
According to 21 CFR 211.110 (a) (3) proper mixing of the ingredients is required to ensure the uniformity of content.
Segregation of the active material may occur when the sample is placed on any vibrating surface that can cause the analytical error. Blending process is a GMP activity, therefore, it should be done and monitor carefully.
Can you give an detail explanation for matrial required to perform blend uniformity test in QC for finished product with example one product
ReplyDelete